Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus

Vaccine

Volumn 33, Issue 4, 2015, Pages 523-526

  Thammavongsa, Vilasack ^a   Rauch, Sabine ^a   Kim, Hwan Keun ^a   Missiakas, Dominique M ^a   Schneewind, Olaf ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Monoclonal antibody; Neonatal bacteremia and meningitis; Protective immunity; Recurrent infection; Staphylococcal protein A; Staphylococcus aureus

Indexed keywords

B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; STAPHYLOCOCCUS PROTEIN A NEUTRALIZING MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; STAPHYLOCOCCUS PROTEIN A; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ARTICLE; CROSS LINKING; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; NEWBORN; NONHUMAN; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ANIMAL; BACTEREMIA; BAGG ALBINO MOUSE; DISEASE MODEL; IMMUNOLOGY; MENINGITIS, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; BACTEREMIA; DISEASE MODELS, ANIMAL; MENINGITIS, BACTERIAL; MICE; MICE, INBRED BALB C; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL PROTEIN A; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRULENCE FACTORS;

EID: 84920627947     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.11.051     Document Type: Article

References (21)

1. Martin J.A., Hamilton B.E., Ventura S.J., Osterman M.J., Kirmeyer S., Mathews T.J., et al. Births: final data for 2009. Natl. Vital Stat. Rep. 2011, 60:1-70.
2. Shane A.L., Hansen N.I., Stoll B.J., Bell E.F., Sánchez P.J., Shankaran S., et al. Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants. Pediatrics 2012, 129:e914-e922.
3. Stoll B.J., Hansen N.I., Adams-Chapman I., Fanaroff A.A., Hintz S.R., Vohr B., et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004, 292:2357-2365.
4. Healy C.M., Palazzi D.L., Edwards M.S., Campbell J.R., Baker C.J. Features of invasive staphylococcal disease in neonates. Pediatrics 2004, 114:953-961.
5. DeJonge M., Burchfield D., Bloom B., Duenas M., Walker W., Polak M., et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 2007, 151:260-265.
6. Benjamin D.K., Schelonka R., White R., Holley H.P., Bifano E., Cummings J., et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol. 2006, 26:290-295.
7. Weisman L.E., Thackray H.M., Steinhorn R.H., Walsh W.F., Lassiter H.A., Dhanireddy R., et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 2011, 128:271-279.
8. Projan S.J., Nesin M., Dunman P.M. Staphylococcal vaccines and immunotherapy: to dream the impossible dream?. Curr. Opin. Pharmacol. 2006, 6:473-479.
9. Forsgren A. Protein A from Staphylococcus aureus. VI. Reaction with subunits from guinea pig γ1- and γ2-globulin. J. Immunol. 1968, 100:927-930.
10. Silverman G.J., Goodyear C.S. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat. Rev. Immunol. 2006, 6:465-475.
11. Falugi F., Kim H.K., Missiakas D.M., Schneewind O. The role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus mBio 2013, 4:e00575-e613.
12. Kim H.K., Cheng A.G., Kim H.-Y., Missiakas D.M., Schneewind O. Non-toxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections. J. Exp. Med. 2010, 207:1863-1870.
13. Kim H.K., Emolo C., DeDent A.C., Falugi F., Missiakas D.M., Schneewind O. Protein A-specific monoclonal antibodies and the prevention of Staphylococcus aureus disease in mice. Infect. Immun. 2012, 80:3460-3470.
14. Placencia F.X., Kong L., Weisman L.E. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin. Pediatr. Res. 2009, 65:420-424.
15. Josefsson E., Hartford O., O'Brien L., Patti J.M., Foster T.J. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 2001, 184:1572-1580.
16. Schaffer A.C., Solinga R.M., Cocchiaro J., Portoles M., Kiser K.B., Risley A., et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immun. 2006, 74:2145-2153.
17. Stranger-Jones Y.K., Bae T., Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Nat. Acad. Sci. USA 2006, 103:16942-16947.
18. Brown E.L., Dumitrescu O., Thomas D., Badiou C., Koers E.M., Choudhury P., et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect. 2009, 15:156-164.
19. Cheng A.G., McAdow M., Kim H.K., Bae T., Missiakas D.M., Schneewind O. Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog. 2010, 6:e1001036.
20. Nimmerjahn F., Ravetch J.V. Fc-gamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
21. Montgomery C.P., Boyle-Vavra S., Adem P.V., Lee J.C., Husain A.N., Clasen J., et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J. Infect. Dis. 2008, 198:561-570.